Does retatrutide cause hair loss? It is a question increasingly asked by patients and clinicians as this investigational triple receptor agonist advances through clinical trials. Retatrutide simultaneously targets GLP-1, GIP, and glucagon receptors, producing substantial weight loss in early studies — and it is precisely this pronounced weight reduction that raises questions about hair shedding. Currently unlicensed in the UK by the MHRA or EMA, retatrutide's full safety profile remains under investigation. This article examines what the available evidence shows, why weight loss medicines can trigger hair changes, and when to seek professional advice.
Summary: Retatrutide has not been formally linked to hair loss in published data, but its pronounced weight loss effect may trigger telogen effluvium — a temporary, nutritionally driven hair shedding — as seen with other incretin-based therapies.
- Retatrutide is an investigational GLP-1, GIP, and glucagon triple receptor agonist not yet licensed by the MHRA or EMA in the UK.
- Hair shedding associated with weight loss medicines is typically telogen effluvium — a self-limiting, diffuse shedding caused by physiological or nutritional stress.
- The published phase 2 trial did not prominently report alopecia among common adverse events; hair-related outcomes were not a predefined endpoint.
- Greater weight loss magnitude with retatrutide compared to semaglutide or tirzepatide may theoretically increase the risk of nutritionally mediated hair shedding.
- Patients experiencing hair loss should have ferritin, full blood count, and thyroid function tested; biotin supplements can interfere with thyroid immunoassays.
- Clinical trial participants should report hair changes to their trial team; for licensed medicines, reports should be submitted via the MHRA Yellow Card scheme.
Table of Contents
- Retatrutide and Hair Loss: What the Evidence Shows
- Why Weight Loss Medicines Can Trigger Hair Shedding
- How Common Is Hair Loss in Retatrutide Clinical Trials?
- When to Speak to a GP or Pharmacist About Hair Changes
- Managing Hair Loss During Treatment: Practical Guidance
- Current MHRA Guidance and Ongoing Safety Monitoring
- Frequently Asked Questions
Am I eligible for weight loss injections?
Find out whether you might be eligible!
Answer a few quick questions to see whether you may be suitable for prescription weight loss injections (like Wegovy® or Mounjaro®).
- No commitment — just a quick suitability check
- Takes about 1 minute to complete
Retatrutide and Hair Loss: What the Evidence Shows
No established regulatory link between retatrutide and hair loss currently exists; published phase 2 data did not prominently feature alopecia, and larger phase 3 safety datasets are still awaited.
Not sure if this is normal? Chat with one of our pharmacists →
Retatrutide is an investigational triple receptor agonist that simultaneously targets the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. A phase 2 randomised controlled trial published in the New England Journal of Medicine in 2023 demonstrated substantial weight loss in adults with obesity, and phase 3 trials are currently ongoing (see ClinicalTrials.gov for current study status). Retatrutide has not yet received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA), and it is not available as a licensed treatment in the UK.
Hair loss — medically referred to as telogen effluvium when associated with physiological stress — has emerged as a topic of interest among patients and clinicians following its association with other incretin-based therapies. For context, tirzepatide (Mounjaro®) is a dual GIP/GLP-1 receptor agonist, and semaglutide (Wegovy®, Ozempic®) is a GLP-1 receptor agonist; both are distinct in their mechanisms from retatrutide's triple agonism. With retatrutide producing pronounced weight loss in early trials, questions about whether it carries a similar risk are understandable and clinically relevant.
It is important to note that there is currently no established regulatory link between retatrutide and hair loss. Available data come primarily from the phase 2 trial, which was not specifically designed or powered to characterise hair-related adverse events. Any discussion of hair loss in this context should therefore be understood as preliminary and subject to revision as larger datasets emerge from ongoing phase 3 studies.
| Side Effect / Factor | Frequency | Severity | Management |
|---|---|---|---|
| Telogen effluvium (diffuse hair shedding linked to rapid weight loss) | Not formally reported in phase 2 trial; possible given degree of weight loss | Mild to moderate; generally self-limiting | Ensure adequate protein, iron, and zinc intake; reassure patient; monitor for regrowth |
| Nausea, vomiting, diarrhoea, constipation (gastrointestinal) | Most commonly reported adverse events in phase 2 trial | Mild to moderate | Dose titration; dietary adjustment; consult trial team or prescriber |
| Nutritional deficiencies (iron, zinc, protein) contributing to hair shedding | Risk increases with caloric restriction; frequency unquantified | Mild to moderate | FBC, serum ferritin; dietitian referral; avoid excessively restrictive eating |
| Patchy hair loss (possible alopecia areata — autoimmune, unrelated to weight loss) | Rare; not attributed to retatrutide | Moderate to severe | GP assessment; dermatology referral if suspected |
| Persistent hair loss (>6 months without regrowth) | Uncommon for telogen effluvium; frequency with retatrutide unknown | Moderate | GP review; thyroid function tests (TSH), FBC, ferritin; consider dermatology referral |
| Scalp changes (redness, scaling, pustules, tenderness) | Not reported in retatrutide trials; unrelated to drug mechanism | Variable; may indicate inflammatory or infectious cause | Prompt GP assessment; exclude tinea capitis, scarring alopecia |
| Biotin supplementation interference with laboratory tests | Not a drug side effect; risk if patient self-medicates with biotin | Low clinical risk if identified; misleading thyroid/other results if unrecognised | Inform GP before blood tests; stop biotin for appropriate period prior to testing (MHRA guidance) |
Why Weight Loss Medicines Can Trigger Hair Shedding
Rapid weight loss can cause telogen effluvium — diffuse hair shedding triggered by caloric restriction, nutritional deficiencies, and metabolic stress — which typically begins two to four months after the triggering event and is usually self-limiting.
To understand the potential relationship between retatrutide and hair changes, it is helpful to understand why rapid or significant weight loss — regardless of the method — can cause hair shedding. The most commonly implicated mechanism is telogen effluvium, a condition in which physiological or nutritional stress causes a disproportionate number of hair follicles to enter the resting (telogen) phase of the hair growth cycle simultaneously. This results in diffuse shedding, typically beginning two to four months after the triggering event. The British Association of Dermatologists (BAD) and NHS.uk both provide accessible patient information on this condition.
Key contributing factors associated with weight loss include:
-
Caloric restriction and nutritional deficiencies: Rapid reductions in caloric intake can deprive hair follicles of essential nutrients, including iron, zinc, and protein — all of which are important for normal hair growth.
-
Physiological stress response: Significant weight loss places metabolic stress on the body, which can disrupt the normal hair cycle.
-
Hormonal changes: Alterations in metabolic hormones during weight loss may theoretically affect follicular activity, though the clinical evidence for this specific mechanism remains limited.
Post-marketing reports of hair shedding have been submitted for some incretin-based medicines; patients and clinicians should check the current UK Summary of Product Characteristics (SmPC) for each licensed product (available via the electronic Medicines Compendium, emc) for the most up-to-date adverse reaction information.
Experiencing these side effects? Our pharmacists can help you navigate them →
Importantly, telogen effluvium is generally self-limiting. In most cases, hair regrowth resumes once the body adapts to its new metabolic state and nutritional intake stabilises. Patients should be reassured that this type of hair loss does not typically indicate permanent follicular damage, as noted in Primary Care Dermatology Society (PCDS) guidance on diffuse hair loss.
How Common Is Hair Loss in Retatrutide Clinical Trials?
Hair loss was not a prominently reported adverse event in the phase 2 retatrutide trial; gastrointestinal effects dominated the safety profile, and hair-related outcomes were not a predefined endpoint.
The primary published data on retatrutide come from a phase 2 randomised controlled trial published in the New England Journal of Medicine in 2023, which evaluated the drug's efficacy and safety in adults with obesity. Participants receiving the highest doses achieved mean weight reductions of approximately 17–24% over 48 weeks — results that substantially exceed those seen with currently licensed agents.
The published phase 2 safety tables did not prominently feature alopecia among the most frequently reported adverse events. The most commonly reported adverse events were gastrointestinal in nature — including nausea, vomiting, diarrhoea, and constipation — a profile consistent with other incretin-based therapies. Whether hair loss occurred at a low frequency or was not captured as a discrete outcome in the published data is not entirely clear from the available report; hair-related outcomes were not a predefined endpoint of the trial.
It is worth noting that:
-
Phase 2 trials typically involve smaller sample sizes, limiting the ability to detect adverse events occurring in fewer than 1–5% of participants.
-
The degree of weight loss achieved with retatrutide is greater than that seen with semaglutide or tirzepatide, which may theoretically increase the risk of nutritionally mediated telogen effluvium.
-
Phase 3 trials are ongoing, and more comprehensive safety data — including detailed reporting of hair-related adverse events — are expected to be published in due course.
Until these larger datasets are available, clinicians and patients should be aware of the possibility of hair shedding without overstating the certainty of this association.
When to Speak to a GP or Pharmacist About Hair Changes
See a GP if hair loss is sudden, patchy, accompanied by systemic symptoms, or persists beyond six months; first-line investigations include FBC, serum ferritin, and thyroid function tests.
Hair shedding during or after significant weight loss is often benign and self-resolving, but there are circumstances in which it warrants professional assessment. Patients using retatrutide — whether within a clinical trial or, in future, as a licensed medicine — should be encouraged to monitor their hair health and seek advice if they notice concerning changes.
Contact a GP or pharmacist if you experience:
-
Sudden or rapidly worsening hair loss that appears disproportionate to normal shedding
-
Patchy hair loss, which may suggest alopecia areata — an autoimmune condition unrelated to weight loss
-
Hair loss accompanied by other symptoms such as fatigue, cold intolerance, or unexplained weight changes, which could indicate thyroid dysfunction
-
Scalp changes including redness, scaling, pustules, or tenderness — these may indicate an inflammatory or infectious cause requiring prompt assessment
-
Hair loss that persists beyond six months without signs of regrowth
Seek urgent dermatology assessment if you notice signs that may suggest scarring alopecia (permanent follicular destruction), such as progressive loss with scalp atrophy, or if tinea capitis (scalp ringworm) is suspected, particularly in children.
A GP can arrange relevant investigations to help identify reversible causes. In line with UK primary care guidance (PCDS), a reasonable first-line screen typically includes a full blood count (FBC), serum ferritin, and thyroid function tests (TSH). Additional tests — such as B12/folate, CRP/ESR, liver and renal function, coeliac screen, zinc, or vitamin D — may be considered based on clinical history and examination findings, rather than routinely.
Important: If you are taking biotin supplements, inform your GP before blood tests are taken. Biotin can interfere with a number of common immunoassays, including thyroid function tests, potentially causing misleading results. The MHRA has issued safety communications on this issue. It is advisable to stop biotin supplementation for an appropriate period before testing, as directed by your GP.
Pharmacists can also provide initial advice and help patients distinguish between normal shedding and clinically significant hair loss, making them a valuable first point of contact.
Managing Hair Loss During Treatment: Practical Guidance
Management focuses on adequate protein and micronutrient intake, gentle hair care, and addressing identified deficiencies; no licensed UK treatment exists specifically for telogen effluvium.
For patients experiencing hair shedding during retatrutide treatment or any significant weight loss programme, a number of practical strategies may help minimise impact and support recovery. These measures are broadly applicable and are not specific to retatrutide, given the likely nutritional and physiological basis of the hair changes.
Nutritional support:
-
Ensure adequate protein intake during active weight loss; if you are unsure whether your diet is meeting your needs, ask your GP or trial team for a referral to a registered dietitian. The British Dietetic Association (BDA) provides guidance on healthy weight management and macronutrient intake.
-
If blood tests identify specific deficiencies — such as low iron (ferritin) or zinc — address these through dietary adjustment or supplementation as directed by your GP or dietitian.
-
Avoid excessively restrictive eating patterns that may compound nutritional deficits.
-
Biotin supplementation is not routinely recommended unless a confirmed deficiency has been identified. Biotin can interfere with common laboratory immunoassays (including thyroid tests), so always inform your healthcare team if you are taking it.
Hair care:
-
Handle hair gently during periods of shedding; avoid excessive heat styling or chemical treatments.
-
Avoid tight hairstyles that place mechanical stress on already-fragile follicles.
Lifestyle and monitoring:
-
Maintain regular follow-up appointments with the prescribing team or trial investigators to report any new or worsening symptoms.
-
Keep a simple diary of hair changes, including timing relative to dose adjustments or periods of rapid weight loss, which can assist clinical assessment.
No specific licensed treatment exists for telogen effluvium in the UK; management is primarily supportive and focused on addressing underlying causes, as outlined in PCDS guidance. Minoxidil, available over the counter, is licensed for androgenetic alopecia; evidence for its use in telogen effluvium is limited, and patients should discuss any supplementation or topical treatments with their GP or a dermatologist before starting.
Current MHRA Guidance and Ongoing Safety Monitoring
Retatrutide has no MHRA or EMA marketing authorisation; trial participants should report adverse events to their trial team, while licensed medicine reactions should be reported via the MHRA Yellow Card scheme.
As of the time of writing, retatrutide has not been granted a marketing authorisation by the MHRA or EMA, and therefore no formal UK product labelling or Summary of Product Characteristics (SmPC) exists. The drug is being evaluated under clinical trial conditions, and all safety data are collected and reviewed as part of the regulatory development process overseen by the trial sponsor and relevant regulatory bodies.
For currently licensed incretin-based medicines, post-marketing reports of hair loss have been submitted by patients and healthcare professionals. The most accurate and up-to-date information on recognised adverse reactions for each product — including semaglutide (Wegovy®, Ozempic®) and tirzepatide (Mounjaro®) — can be found in their respective UK SmPCs, available via the electronic Medicines Compendium (emc) at medicines.org.uk. Clinicians and patients should consult these documents rather than relying on general statements about class effects.
Reporting adverse events — understanding the correct pathway:
-
If you are a clinical trial participant, you should report any adverse effects — including hair changes — directly to your trial team. The trial sponsor is responsible for collecting and submitting this information to the relevant regulatory authority. This is distinct from the Yellow Card scheme.
-
For licensed or unlicensed medicines used outside of a clinical trial, patients and healthcare professionals in the UK are encouraged to report suspected adverse drug reactions via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk or via the Yellow Card app). Yellow Card reports from patients and clinicians contribute directly to ongoing pharmacovigilance and help identify emerging safety signals.
Once retatrutide progresses to regulatory submission, a comprehensive safety profile — including any signal related to hair loss — will be scrutinised as part of the benefit-risk evaluation. Patients and healthcare professionals seeking the most current information on retatrutide's development status should consult ClinicalTrials.gov, published peer-reviewed literature, and MHRA or EMA communications as the evidence base continues to evolve.
Frequently Asked Questions
Does retatrutide cause hair loss, and how does it compare to semaglutide or tirzepatide?
Retatrutide has not been formally identified as a cause of hair loss in published clinical trial data, unlike semaglutide and tirzepatide where post-marketing hair shedding reports have been submitted. However, because retatrutide produces greater weight loss than either of those medicines, the risk of nutritionally driven telogen effluvium may be at least as high, if not higher.
Is hair loss from weight loss injections permanent?
Hair loss linked to weight loss medicines is almost always telogen effluvium, which is temporary and self-limiting — hair typically regrows once the body adapts and nutritional intake stabilises. Permanent follicular damage is not expected with this type of shedding, though persistent or patchy loss should be assessed by a GP to rule out other causes.
How long after starting retatrutide might hair shedding begin?
Telogen effluvium typically begins two to four months after the physiological trigger — in this case, significant weight loss — rather than immediately after starting treatment. This delay often means patients do not initially connect the hair shedding to their weight loss medicine.
Can I take biotin supplements to help with hair loss while on a weight loss medicine?
Biotin supplementation is not routinely recommended for hair loss unless a confirmed deficiency has been identified, and it should be used with caution because it can interfere with common laboratory immunoassays, including thyroid function tests, potentially producing misleading results. Always inform your GP or healthcare team if you are taking biotin before any blood tests are arranged.
Can I get retatrutide on the NHS or privately in the UK right now?
Retatrutide is not currently available on the NHS or through private prescription in the UK, as it has not received marketing authorisation from the MHRA or EMA. It is only accessible through participation in authorised clinical trials; patients interested in trial eligibility should speak to their GP or check ClinicalTrials.gov.
What nutrients should I make sure I'm getting enough of to protect my hair during significant weight loss?
Adequate protein, iron (ferritin), and zinc are the most important nutrients for maintaining normal hair growth during weight loss, and deficiencies in these are the most common nutritional drivers of telogen effluvium. A registered dietitian — referrable through your GP or trial team — can help ensure your diet meets your needs without excessively restrictive eating patterns.
The health-related content published on this site is based on credible scientific sources and is periodically reviewed to ensure accuracy and relevance. Although we aim to reflect the most current medical knowledge, the material is meant for general education and awareness only.
The information on this site is not a substitute for professional medical advice. For any health concerns, please speak with a qualified medical professional. By using this information, you acknowledge responsibility for any decisions made and understand we are not liable for any consequences that may result.
Any third-party brands or services referenced on this site are included for informational purposes only; we are entirely independent and have no affiliation, partnership, or collaboration with any companies mentioned.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Heading 6
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Block quote
Ordered list
- Item 1
- Item 2
- Item 3
Unordered list
- Item A
- Item B
- Item C
Bold text
Emphasis
Superscript
Subscript
